Up to 95%
Sensitivity achieved in preliminary HCC Panel studies
33
Patents across three international patent families
1,400+
Patient serum samples in Glycotest’s proprietary clinical validation biobank
20
Leading medical centers participating in the clinical validation program
Advancing Early Detection Through Glycoprotein Science
Transforming Liver Cancer Detection
Liver cancer is one of the fastest growing causes of cancer-related death worldwide. When detected early, however, many patients are eligible for potentially curative treatment.
Glycotest is developing blood tests designed to improve the surveillance and early detection of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Our goal is to help physicians identify disease earlier, improve patient outcomes and reduce healthcare costs through simple, non-invasive blood tests.
Novel biomarkers.
New possibilities for earlier detection.
Up to 95%
Sensitivity achieved in preliminary HCC Panel studies
Why Earlier Detection Matters
Current surveillance methods can miss a significant proportion of early-stage liver cancers, meaning many patients are diagnosed only after curative treatment is no longer possible.
At the same time, the number of people at risk continues to increase as chronic liver disease and metabolic dysfunction-associated steatohepatitis (MASH/NASH) become more prevalent worldwide. This growing clinical need highlights the importance of more accurate, accessible and non-invasive approaches to liver cancer surveillance.
The HCC Panel
Our lead program is the HCC Panel, an innovative blood test being developed for the surveillance of hepatocellular carcinoma in patients at increased risk of liver cancer.
In preliminary clinical studies, the HCC Panel has demonstrated performance of up to 95% sensitivity at 90% specificity, supporting Glycotest’s ambition to establish a new clinical standard for liver cancer surveillance.
3 Proprietary Glycotest Glycoprotein Biomarkers
Disease-associated glycoprotein signals
3 Established Serum Biomarkers
Additional biomarker inputs
Patient Age & Sex
Clinical characteristics
Proprietary Algorithm
Integrated multi-parameter analysis
Up to
95%
Sensitivity
Up to
90%
Specificity
The panel combines proprietary glycoprotein biomarkers with established serum biomarkers and patient data through a proprietary algorithm to generate an HCC likelihood score.
Measuring Two Kinds of Disease Signal
Abnormal Glycan Profiles
Changes in glycan structures on selected serum glycoproteins provide an important indicator of disease.
Disease-specific Glycoprotein Patterns
The platform also analyzes patterns of glycoproteins with abnormal glycan profiles associated with specific liver diseases, including hepatocellular carcinoma, cholangiocarcinoma and liver fibrosis.
Why Glycotest?
01
Proprietary Platform
A differentiated diagnostics platform built on proprietary glycoprotein biomarkers designed to detect subtle biological changes associated with liver disease.
02
Earlier Detection
Developing highly sensitive blood tests designed to identify liver cancer when treatment remains most effective.
03
Expanding Pipeline
Advancing a portfolio of diagnostic programs targeting hepatocellular carcinoma, cholangiocarcinoma and liver fibrosis.
04
Clinical Validation
Progressing towards clinical validation through strategic partnerships, leading clinical collaborations and a strong intellectual property portfolio.
OUR MISSION
To transform liver cancer outcomes by detecting disease when it is still curable through simple, routine blood testing.
EARLIER DETECTION.
GREATER POSSIBILITIES.
Recent developments
Read the latest corporate announcements, scientific developments and company news from Glycotest.
Glycotest Licenses Novel Biomarker Intellectual Property from the Medical University of South Carolina to Advance Next-Generation Liver Fibrosis Staging Test
Glycotest, Inc. announced today that it has executed a license agreement with the Zucker Institute for Innovation Commercialization (ZI), the commercialization entity advancing technologies originated from the Medical University of South Carolina (MUSC), for…
Read more →Glycotest secures US$3.22 million to advance liver cancer diagnostic platform
Glycotest has successfully completed the first closing of a US$3.22 million fundraising to accelerate the development and commercialization of its next-generation blood test for liver cancer.The financing includes approximately US$1.05 million in new cash…
Read more →Glycotest’s HCC Panel test for early-stage liver cancer receives additional patent protection in Japan, Singapore, Australia, the Philippines, Hong Kong and China.
Glycotest’s HCC Panel test for early-stage liver cancer receives additional patent protection in Japan, Singapore, Australia, the Philippines, Hong Kong and China.
Read more →